{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T16:21:57Z","timestamp":1795191717131,"version":"4.10.3"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lanepe.2026.101826","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:54:33Z","timestamp":1787784873000},"page":"101826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Patient characteristics, treatment patterns, and survival across estrogen receptor expression subgroups in HER2-negative breast cancer: a population-based cohort study"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4098-3246","authenticated-orcid":false,"given":"Qiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5598-0243","authenticated-orcid":false,"given":"Ceren","family":"Boyaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8304-2462","authenticated-orcid":false,"given":"Ioannis","family":"Zerdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7811-9317","authenticated-orcid":false,"given":"Irma","family":"Fredriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3214-9075","authenticated-orcid":false,"given":"Xinsong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0972-4633","authenticated-orcid":false,"given":"Balazs","family":"Acs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2026.101826_bib1","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American society of clinical oncology\/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lanepe.2026.101826_bib25","article-title":"Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study","volume":"40","author":"Acs","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanepe.2026.101826_bib2","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Abe","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2026.101826_bib4","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lanepe.2026.101826_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.21037\/tbcr-20-24","article-title":"Breast cancer patients with low estrogen receptor expression gain no significant survival benefit from endocrine therapy: a real-world study from China","volume":"1","author":"Wang","year":"2020","journal-title":"Transl Breast Cancer Res"},{"key":"10.1016\/j.lanepe.2026.101826_bib6","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1245\/s10434-023-14835-z","article-title":"Defining the biology of estrogen receptor-low-positive breast cancer","volume":"31","author":"Higgins","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.lanepe.2026.101826_bib7","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-019-6846-6","article-title":"Validation of data quality in the Swedish National Register for Breast Cancer","volume":"19","author":"L\u00f6fgren","year":"2019","journal-title":"BMC Public Health"},{"key":"10.1016\/j.lanepe.2026.101826_bib8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/his.13089","article-title":"Further evidence to support bimodality of oestrogen receptor expression in breast cancer","volume":"70","author":"Muftah","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.lanepe.2026.101826_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104508","article-title":"Prognosis, clinicopathological characteristics, and treatment patterns of patients with ER-intermediate-positive breast cancer undergoing long-term follow-up","volume":"10","author":"Matsumoto","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.lanepe.2026.101826_bib10","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/his.12412","article-title":"Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression","volume":"65","author":"Zhang","year":"2014","journal-title":"Histopathology"},{"key":"10.1016\/j.lanepe.2026.101826_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-022-00465-3","article-title":"RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer","volume":"8","author":"Staaf","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.lanepe.2026.101826_bib13","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/0895-4356(95)00048-8","article-title":"Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates","volume":"48","author":"Peduzzi","year":"1995","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.lanepe.2026.101826_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-023-00543-0","article-title":"Immune landscape of breast tumors with low and intermediate estrogen receptor expression","volume":"9","author":"Voorwerk","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.lanepe.2026.101826_bib15","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/jnci\/djae178","article-title":"Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer","volume":"116","author":"Massa","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lanepe.2026.101826_bib16","first-page":"199","article-title":"A real-world data retrospective cohort study of low estrogen receptor-positive early breast cancer: natural history and treatment outcomes","volume":"14","author":"Bari","year":"2022","journal-title":"Breast Cancer"},{"key":"10.1016\/j.lanepe.2026.101826_bib17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.clbc.2024.11.020","article-title":"Breast cancers with intermediate estrogen receptor expression: characteristics, prognosis and treatment","volume":"25","author":"Voutsadakis","year":"2025","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.lanepe.2026.101826_bib18","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO-24-02263","article-title":"Endocrine therapy omission in estrogen receptor\u2013low (1%-10%) early-stage breast cancer","volume":"43","author":"Choong","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lanepe.2026.101826_bib19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/jnci\/djx270","article-title":"Intratumor heterogeneity of the estrogen receptor and the long-term risk of fatal Breast cancer","volume":"110","author":"Lindstr\u00f6m","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lanepe.2026.101826_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100607","article-title":"The conflicting prognostic role of the stroma\u2013tumor ratio in breast cancer molecular subtypes","volume":"37","author":"Ghannam","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.lanepe.2026.101826_bib21","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s12282-025-01745-z","article-title":"Breast tumors with intermediate ER expression differ biologically from ER-low tumors and exhibit a more favorable prognosis","volume":"32","author":"Ueki","year":"2025","journal-title":"Breast Cancer"},{"key":"10.1016\/j.lanepe.2026.101826_bib22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/JCO.2007.14.8411","article-title":"Does estrogen receptor-negative\/progesterone receptor-positive breast carcinoma exist? [3]","volume":"26","author":"De Maeyer","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lanepe.2026.101826_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2017.00227","article-title":"Tumor heterogeneity in breast cancer","volume":"4","author":"Turashvili","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.lanepe.2026.101826_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051166","article-title":"Variability in breast cancer biomarker assessment and the effect on oncological treatment decisions: a nationwide 5-year population-based study","volume":"13","author":"Acs","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T15:54:14Z","timestamp":1795190054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226002383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"alternative-id":["S2666776226002383"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101826","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient characteristics, treatment patterns, and survival across estrogen receptor expression subgroups in HER2-negative breast cancer: a population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101826"}}